story of the week
Dabrafenib Plus Trametinib vs Dabrafenib in Metastatic BRAF V600E/K–Mutant Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dabrafenib Plus Trametinib Versus Dabrafenib Monotherapy in Patients With Metastatic BRAF V600E/K-Mutant Melanoma: Long-Term Survival and Safety Analysis of a Phase 3 Study
Ann. Oncol 2017 May 05;[EPub Ahead of Print], GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, C Garbe, T Jouary, A Hauschild, V Chiarion-Sileni, C Lebbe, M Mandalà, M Millward, A Arance, I Bondarenko, JBAG Haanen, J Hansson, J Utikal, V Ferraresi, P Mohr, V Probachai, D Schadendorf, P Nathan, C Robert, A Ribas, MA Davies, SR Lane, JJ Legos, B Mookerjee, JJ GrobFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.